Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Medtech catalyst setup: FDA cleared Control-IQ+ for pregnancy in type 1 diabetes on 2026-04-27, CE mark expansion in Europe was announced on 2026-06-05 for pregnancy use and type 2 diabetes, Q1 showed record pump shipments/sales/gross margin, and the stock is up about 20% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠Fragile breakout ⢠Overhead resistance Support Level: $16.90-$17.10 Resistance Level: $17.60-$18.10 TNDM remains constructive over the last month with higher lows and a gain from its starting point, but the failed push to $18.10 and drop back to $16.90 suggest the rally is still fragile; support is around $16.90-$17.10 and resistance is near $17.60-$18.10
Sentiment & News
Key News Insights: ⢠Device Compatibility ⢠Earnings Scheduled ⢠Investor Scrutiny Tandem Diabetes Care is expanding t:slim X2 compatibility with Abbott's Libre 3 Plus in five markets while investors await its Aug. 6 Q2 earnings update and continued stock scrutiny.
AI Summary
TNDM is now an execution story rather than just a product story, with Q1's record revenue, margin improvement, and first positive adjusted EBITDA since 2022 showing real operating progress, but investors should treat it as a turnaround until Q2 proves those gains are durable enough to justify a re-rating.
Description
Tandem Diabetes Care, Inc. develops and sells insulin delivery systems and companion software for people with insulin-dependent diabetes in the United States and abroad. Its core offering is a modular pump platform that includes the pump, disposable insulin cartridge and infusion set, with versions that integrate automated insulin-delivery algorithms and continuous glucose monitor data; the company also provides software update tools and web and mobile applications for therapy data management. Tandem maintains development and commercialization agreements with CGM manufacturers including Dexcom and Abbott, and is headquartered in San Diego, California; it was incorporated in 2006 and adopted its current name in 2008.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 8 | Jun 15 | TNDM | Tandem Diabetes Care, Inc. | Medtech catalyst setup: FDA cleared Control-IQ+ for pregnancy in type 1 diabetes on 2026-04-27, CE mark expansion in Europe was announced on 2026-06-05 for pregnancy use and type 2 diabetes, Q1 showed record pump shipments/sales/gross margin, and the stock is up about 20% over 21 trading days. | Closed | -9.3% |